143
views
0
recommends
+1 Recommend
0 collections
    2
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) a

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The critical role of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working relationship between the physician and the microbiologists who provide enormous value to the health care team. This document, developed by both laboratory and clinical experts, provides information on which tests are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. Sections are divided into anatomic systems, including Bloodstream Infections and Infections of the Cardiovascular System, Central Nervous System Infections, Ocular Infections, Soft Tissue Infections of the Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract infections, Infections of the Gastrointestinal Tract, Intraabdominal Infections, Bone and Joint Infections, Urinary Tract Infections, Genital Infections, and Skin and Soft Tissue Infections; or into etiologic agent groups, including Tickborne Infections, Viral Syndromes, and Blood and Tissue Parasite Infections. Each section contains introductory concepts, a summary of key points, and detailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or have prolonged turnaround times. There is redundancy among the tables and sections, as many agents and assay choices overlap. The document is intended to serve as a reference to guide physicians in choosing tests that will aid them to diagnose infectious diseases in their patients.

          Related collections

          Most cited references233

          • Record: found
          • Abstract: not found
          • Article: not found

          Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Rapid diagnostic tests for malaria parasites.

            Malaria presents a diagnostic challenge to laboratories in most countries. Endemic malaria, population movements, and travelers all contribute to presenting the laboratory with diagnostic problems for which it may have little expertise available. Drug resistance and genetic variation has altered many accepted morphological appearances of malaria species, and new technology has given an opportunity to review available procedures. Concurrently the World Health Organization has opened a dialogue with scientists, clinicians, and manufacturers on the realistic possibilities for developing accurate, sensitive, and cost-effective rapid diagnostic tests for malaria, capable of detecting 100 parasites/microl from all species and with a semiquantitative measurement for monitoring successful drug treatment. New technology has to be compared with an accepted "gold standard" that makes comparisons of sensitivity and specificity between different methods. The majority of malaria is found in countries where cost-effectiveness is an important factor and ease of performance and training is a major consideration. Most new technology for malaria diagnosis incorporates immunochromatographic capture procedures, with conjugated monoclonal antibodies providing the indicator of infection. Preferred targeted antigens are those which are abundant in all asexual and sexual stages of the parasite and are currently centered on detection of HRP-2 from Plasmodium falciparum and parasite-specific lactate dehydrogenase or Plasmodium aldolase from the parasite glycolytic pathway found in all species. Clinical studies allow effective comparisons between different formats, and the reality of nonmicroscopic diagnoses of malaria is considered.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

              Toxins A and B are the primary virulence factors of Clostridium difficile. Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada. We characterised the dominant strain of this epidemic to determine whether it produces higher amounts of toxins A and B than those produced by non-epidemic strains. We obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec. Additional isolates from the USA, Canada, and the UK were included to increase the genetic diversity of the toxinotypes tested. Isolate characterisation included toxinotyping, pulsed-field gel electrophoresis (PFGE), PCR ribotyping, detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B (tcdC). By use of an enzyme-linked immunoassay, we measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates. The epidemic strain was characterised as toxinotype III, North American PFGE type 1, and PCR-ribotype 027 (NAP1/027). This strain carried the binary toxin gene cdtB and an 18-bp deletion in tcdC. We isolated this strain from 72 patients with C difficile-associated disease (58 [67%] of 86 with health-care-associated disease; 14 [37%] of 38 with community-acquired disease). Peak median (IQR) toxin A and toxin B concentrations produced in vitro by NAP1/027 were 16 and 23 times higher, respectively, than those measured in isolates representing 12 different PFGE types, known as toxinotype 0 (toxin A, median 848 microg/L [IQR 504-1022] vs 54 microg/L [23-203]; toxin B, 180 microg/L [137-210] vs 8 microg/L [5-25]; p<0.0001 for both toxins). The severity of C difficile-associated disease caused by NAP1/027 could result from hyperproduction of toxins A and B. Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.
                Bookmark

                Author and article information

                Journal
                Clin Infect Dis
                Clin. Infect. Dis
                cid
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press
                1058-4838
                1537-6591
                15 August 2013
                15 August 2013
                : 57
                : 4
                : e22-e121
                Affiliations
                [1 ] Department of Pathology, Stanford University School of Medicine , Stanford, California
                [2 ] Cepheid, R&D , Sunnyvale, California
                [3 ] Microbiology Technical Services, LLC , Dunwoody, Georgia
                [4 ] Department of Medicine and Pathology, Robert Wood Johnson Medical School , New Brunswick, New Jersey
                [5 ] Department of Clinical Pathology, Cleveland Clinic , Cleveland, Ohio
                [6 ] Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina
                [7 ] Department of Pathology, NorthShore University HealthSystem , Evanston, Illinois
                [8 ] Scientific Affairs, BD Diagnostics , Sparks, Maryland
                [9 ] Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland
                [10 ] Department of Pathology, Medical College of Wisconsin , Milwaukee, Wisconsin
                [11 ] bioMerieux, Inc, Durham, North Carolina
                [12 ] Department of Pathology and Immunology, Washington University School of Medicine , St. Louis, Missouri
                [13 ] Department of Pathology, William Beaumont Hospital to Beaumont Health System , Royal Oak, Michigan
                [14 ] Department of Pathology, Geisel School of Medicine at Dartmouth , Lebanon, New Hampshire
                [15 ] Department of Pathology, Brown Alpert Medical School , Providence, Rhode Island
                [16 ] Department of Laboratory Medicine, University of Louisville , Kentucky
                [17 ] Department of Pathology, Virginia Commonwealth University Medical Center , Richmond, Virginia
                [18 ] Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota
                Author notes
                [a]

                Although accurate and authoritative, IDSA considers adherence to the recommendations in this guide to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.

                Correspondence: Ellen Jo Baron, PhD, Cepheid, R&D, 1315 Chesapeake Terrace, Sunnyvale, CA 94089, USA ( ejbaron@ 123456stanford.edu ).
                Article
                cit278
                10.1093/cid/cit278
                3719886
                23845951
                d9b8d1b3-5a06-4338-af7e-05be534bd788
                © The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@ 123456oup.com .

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 19 April 2013
                : 22 April 2013
                Categories
                Idsa Guideline
                Medical Guideline
                Medical Guideline

                Infectious disease & Microbiology
                laboratory diagnosis,microbiology testing,specimen processing,physician-laboratory communication,medical laboratories

                Comments

                Comment on this article